Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation

Abstract

Rivaroxaban and dabigatran demonstrated better persistence than VKA at Day 360. Furthermore, rivaroxaban was associated with better persistence and adherence than dabigatran. Further studies are needed to identify factors responsible for this difference and evaluate the impact on outcomes.